Sarepta rebounds after sell-off

Shares of Sarepta Therapeutics (SRPT +2.7%) rebound from Wednesday's sell-off.

Perhaps helping to allay fears is TheStreet's Adam Feuerstein who penned a "rousing rebuttal" to the two SRPT short articles that appeared on SA Wednesday.

"Neither article said anything new about SRPT or eteplirsen that hasn't been already debated endlessly," Feuerstein says, adding that "the eteplirsen data are what they are [and] investors find the data convincing or not."

Feuerstein also notes that there will likely never be an "apples-to-apples comparison of dystrophin production between eteplirsen and drisapersen" but the data certainly seems to suggest that eteplirsen "produces more functional dystrophin."

For reference, see: SRPT falls as article questions eteplirsen study.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs